Reports 2022 revenue $3.9M vs. $31.3M last year. Alon Seri-Levy, Ph.D., CEO of Sol-Gel, stated, "With the recent acquisition of patidegib, a Breakthrough-designated Orphan Drug candidate with a market potential of over $300M, Sol-Gel has successfully pivoted towards the attractive rare disease segment and the major unmet need for Gorlin syndrome patients. We are also extremely encouraged by the rapid market uptake of our Galderma-partnered products, TWYNEO and EPSOLAY, by prescribers, patients, and payors during their first year on the market and remain confident about prospects to improve TWYNEO and EPSOLAY reimbursement and profitability over time. We will seek to out-license non-U.S. rights for TWYNEO and EPSOLAY and generate non-dilutive income."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLGL:
- Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
- Sol-Gel announces $22.8M registered direct, private placement offerings
- Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
- Sol-Gel Technologies acquires Phase 3 Gorlin syndrome candidate patidegib
- Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
